Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADIL trial of adjuvant durvalumab after neoadjuvant chemoimmunotherapy and surgery in resectable NSCLC
2025-524439-38-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Sep 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Adjuvant durvalumab with No adjuvant immunotherapy / observation (2 arms). Primary endpoint: Disease-free survival. Planned start Sep 2026; status: authorised.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-524439-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524439-38-00.